Navigation Links
ELECTRA 1400C Coagulation System

ProductsELECTRA 1400C Coagulation System
Company Beckman Coulter, Inc.
Item ELECTRA 1400C Coagulation System
Features 
  • Simultaneous execution of clotting and chromogenic assays in random access
  • Extended walkaway capabilities with 35 sample positions for routine and 3 positions available for STAT
  • Integrated barcode reader ensures accurate patient identification
  • Sample liquid level sensing with customized needle setting of the maximum depth
  • Walkaway with 280 reaction cuvettes on board
  • 4 refrigerated reagent positions for clotting and chromogenic assays; and 13 additional positions for controls, calibrators, deficient plasma and diluents
  • Customized Quality Control Program allows storage, retrieval and manipulation of patient data
  • Advanced, intuitive computer technology that offers full alpha-numeric capabilities and standard ASTM communication that allows for easy interface with LIS/HIS systems
Description The advanced features of the ELECTRA 1400C are designed to achieve low daily operational costs with extended walkaway capabilities. This system includes automated primary tube sampling and performs APTT, PT, fibrinogen and factor assays in a single setup. It also has an integrated barcode reader and automatic preparation of reference curves and patient sample dilutions to ensure accuracy. Plus, it can perform both clotting and chromogenic testing in random access.
Info Beckman Coulter, Inc.
Customer Service: (800) 742-2345
Web site: http://www.beckmancoulter.com

Related medicine products :

1. ACL 100 Coagulation Analyzer
2. Electra 1800C Coagulation System
3. ACL Advance Coagulation Analyzer
4. ACL 9000 Coagulation Analyzer
5. Automated Blood Coagulation Analyzer
6. MLA Electra 750 Coagulation Analyzer
7. Cascade M Manual Coagulation Analyzer
8. Cascade M-4 Manual Coagulation Analyzer
9. Blood Coagulation Analyzer CG Series
10. Non-Stick Bipolar Coagulation Forceps
11. ACT PLUS Automated Coagulation Timer System
Breaking Medicine News(10 mins):Health News:Securities Class Action Filed by Shepherd, Finkelman, Miller & Shah, LLP on Behalf of Hemispherx Biopharma Securities Purchasers Between February 18, 2009 and November 2, 2009 2Health News:Securities Class Action Filed by Shepherd, Finkelman, Miller & Shah, LLP on Behalf of Hemispherx Biopharma Securities Purchasers Between February 18, 2009 and November 2, 2009 3Health News:Securities Class Action Filed by Shepherd, Finkelman, Miller & Shah, LLP on Behalf of Hemispherx Biopharma Securities Purchasers Between February 18, 2009 and November 2, 2009 4Health News:Procter & Gamble Announces Appointment of Director 2Health News:Possible ovarian cancer treatment target identified 2Health News:Testosterone Gets Bad Rap: Study 2Health News:Testosterone Gets Bad Rap: Study 3Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 2Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 3Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 4Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 5Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 6Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 7Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 8Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 9Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 10Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 11Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 12Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 13Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 14Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 15Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 16Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 17Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 18Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 19Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 20Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 21
Breaking Medicine Technology:Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 2Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 3Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 4Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 5Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 6Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 7Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 8Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 9Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 2Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 3Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 4Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 5Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 6Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 7Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective 2Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective 3Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective 4Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective 5Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective 6Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective 7Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective 8Members of National CHD Organization Unite for Little Hearts Celebration and Assemble for Picture of Hope 48154 1Members of National CHD Organization Unite for Little Hearts Celebration and Assemble for Picture of Hope 48154 2Keryx Biopharmaceuticals Reports Positive Phase 2 Study Results of Zerenex 28Ferric Citrate 29 for the Treatment of Hyperphosphatemia in End Stage Re 12516 1Keryx Biopharmaceuticals Reports Positive Phase 2 Study Results of Zerenex 28Ferric Citrate 29 for the Treatment of Hyperphosphatemia in End Stage Re 12516 2Keryx Biopharmaceuticals Reports Positive Phase 2 Study Results of Zerenex 28Ferric Citrate 29 for the Treatment of Hyperphosphatemia in End Stage Re 12516 3Keryx Biopharmaceuticals Reports Positive Phase 2 Study Results of Zerenex 28Ferric Citrate 29 for the Treatment of Hyperphosphatemia in End Stage Re 12516 4Keryx Biopharmaceuticals Reports Positive Phase 2 Study Results of Zerenex 28Ferric Citrate 29 for the Treatment of Hyperphosphatemia in End Stage Re 12516 5Intarcia Therapeutics Inc Presents ITCA 650 Phase 1b Study Results as a Late Breaker at the American Diabetes Association 69th Scientific Sessions 12513 1Intarcia Therapeutics Inc Presents ITCA 650 Phase 1b Study Results as a Late Breaker at the American Diabetes Association 69th Scientific Sessions 12513 2Intarcia Therapeutics Inc Presents ITCA 650 Phase 1b Study Results as a Late Breaker at the American Diabetes Association 69th Scientific Sessions 12513 3Intarcia Therapeutics Inc Presents ITCA 650 Phase 1b Study Results as a Late Breaker at the American Diabetes Association 69th Scientific Sessions 12513 4